LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

作者：B. Besse, SH Lee, Shun Lü, Daniil Stroyakovskiy, O. Yazıcı, Jerónimo Rodríguez Cid, H. Hayashi, Danny Nguyen, James Chih‐Hsin Yang, Maya Gottfried, Ana Caroline Zimmer Gelatti, Scott Peter Owen, S-H.I. Ou, Marguerite Ennis, Seema Niphadkar Sethi, J.M. Bauml, J. Zhang, J.C. Curtin, B.C. Cho · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.2297 · 被引用次数：50 · 研究领域：Lung Cancer Treatments and Mutations、Gastric Cancer Management and Outcomes、Colorectal Cancer Treatments and Studies